OrthoPediatrics (KIDS) Competitors $19.20 +1.30 (+7.26%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$19.20 0.00 (0.00%) As of 08/7/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KIDS vs. EYE, LMAT, LQDA, CNMD, ENOV, SSII, CDRE, NVCR, AORT, and ESTAShould you be buying OrthoPediatrics stock or one of its competitors? The main competitors of OrthoPediatrics include National Vision (EYE), LeMaitre Vascular (LMAT), Liquidia Technologies (LQDA), CONMED (CNMD), Enovis (ENOV), SS Innovations International (SSII), Cadre (CDRE), NovoCure (NVCR), Artivion (AORT), and Establishment Labs (ESTA). These companies are all part of the "medical equipment" industry. OrthoPediatrics vs. Its Competitors National Vision LeMaitre Vascular Liquidia Technologies CONMED Enovis SS Innovations International Cadre NovoCure Artivion Establishment Labs OrthoPediatrics (NASDAQ:KIDS) and National Vision (NASDAQ:EYE) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk. Is KIDS or EYE more profitable? National Vision has a net margin of -0.75% compared to OrthoPediatrics' net margin of -18.92%. National Vision's return on equity of 3.56% beat OrthoPediatrics' return on equity.Company Net Margins Return on Equity Return on Assets OrthoPediatrics-18.92% -6.35% -4.75% National Vision -0.75%3.56%1.49% Do institutionals & insiders have more ownership in KIDS or EYE? 69.1% of OrthoPediatrics shares are held by institutional investors. 32.7% of OrthoPediatrics shares are held by insiders. Comparatively, 2.7% of National Vision shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger valuation and earnings, KIDS or EYE? National Vision has higher revenue and earnings than OrthoPediatrics. National Vision is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrthoPediatrics$204.73M2.28-$37.82M-$1.79-10.73National Vision$1.82B1.05-$28.50M-$0.33-73.24 Which has more risk and volatility, KIDS or EYE? OrthoPediatrics has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, National Vision has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Does the media favor KIDS or EYE? In the previous week, National Vision had 9 more articles in the media than OrthoPediatrics. MarketBeat recorded 25 mentions for National Vision and 16 mentions for OrthoPediatrics. National Vision's average media sentiment score of 1.14 beat OrthoPediatrics' score of 0.11 indicating that National Vision is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OrthoPediatrics 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral National Vision 9 Very Positive mention(s) 7 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend KIDS or EYE? OrthoPediatrics presently has a consensus target price of $36.29, indicating a potential upside of 88.99%. National Vision has a consensus target price of $24.73, indicating a potential upside of 2.31%. Given OrthoPediatrics' stronger consensus rating and higher probable upside, analysts clearly believe OrthoPediatrics is more favorable than National Vision.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OrthoPediatrics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86National Vision 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummaryNational Vision beats OrthoPediatrics on 9 of the 15 factors compared between the two stocks. Get OrthoPediatrics News Delivered to You Automatically Sign up to receive the latest news and ratings for KIDS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KIDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KIDS vs. The Competition Export to ExcelMetricOrthoPediatricsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$434.73M$6.80B$5.48B$9.57BDividend YieldN/A1.35%4.00%4.18%P/E Ratio-10.7324.4429.8825.14Price / Sales2.2858.73440.45103.02Price / CashN/A20.5535.9458.58Price / Book1.315.528.105.59Net Income-$37.82M$178.18M$3.26B$265.48M7 Day Performance-5.84%-0.57%0.65%1.22%1 Month Performance-11.44%-5.36%2.44%0.39%1 Year Performance-32.11%6.18%27.59%23.47% OrthoPediatrics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KIDSOrthoPediatrics3.8976 of 5 stars$19.20+7.3%$36.29+89.0%-29.2%$434.73M$204.73M-10.73200Earnings ReportAnalyst ForecastEYENational Vision3.0375 of 5 stars$24.48-2.2%$23.00-6.0%+121.1%$1.98B$1.82B-74.1813,411Trending NewsEarnings ReportAnalyst ForecastLMATLeMaitre Vascular2.3761 of 5 stars$82.47+0.0%$97.83+18.6%+17.4%$1.86B$219.86M41.65490Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionLQDALiquidia Technologies3.4698 of 5 stars$19.82+1.1%$26.89+35.7%+79.9%$1.68B$14M-12.5450Insider TradeCNMDCONMED4.4058 of 5 stars$50.05-1.8%$62.20+24.3%-19.9%$1.58B$1.32B13.173,900ENOVEnovis3.1716 of 5 stars$27.36-0.7%$55.60+103.2%-29.8%$1.57B$2.11B-1.967,367News CoverageEarnings ReportSSIISS Innovations InternationalN/A$7.20+0.3%N/AN/A$1.39B$20.65M0.004Gap UpCDRECadre3.1377 of 5 stars$33.60-0.9%$37.50+11.6%-5.1%$1.38B$567.56M35.372,284News CoverageEarnings ReportNVCRNovoCure4.576 of 5 stars$11.64-3.3%$28.79+147.3%-40.1%$1.34B$605.22M-7.461,488AORTArtivion1.8943 of 5 stars$31.32-0.3%$32.40+3.4%+30.4%$1.34B$388.54M-62.641,600News CoverageEarnings ReportESTAEstablishment Labs1.7458 of 5 stars$42.48+0.2%$54.83+29.1%+1.1%$1.23B$166.02M-13.701,018News CoverageEarnings Report Related Companies and Tools Related Companies EYE Competitors LMAT Competitors LQDA Competitors CNMD Competitors ENOV Competitors SSII Competitors CDRE Competitors NVCR Competitors AORT Competitors ESTA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KIDS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OrthoPediatrics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share OrthoPediatrics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.